Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk ...

Prof. Hendrik Bessembinder showed that the vast majority of gains from the US stock market came from only a few selected stocks: Four out of every seven common stocks that have appeared in the CRSP ...

There's never a dull moment if you're a fan of Cathie Wood. The aggressive growth investor is the co-founder, CEO, and stock picker at Ark Invest. She publishes her daily transactions at the end of ...

NASDAQ:CRSP opened at $49.00 on Monday. The company’s fifty day moving average price is $47.14 and its 200-day moving average price is $53.59. CRISPR Therapeutics has a 1-year low of $37.55 and ...

The Third Avenue Small-Cap Value Fund returned +8.35% during Q3 2024 vs. +10.15% for the Fund’s benchmark index. Click here ...

View Our Latest Research Report on CRISPR Therapeutics CRISPR Therapeutics Price Performance Shares of CRSP stock opened at $48.92 on Friday. The company has a market cap of $4.15 billion, a PE ...

Incyte Corporation INCY is scheduled to report third-quarter 2024 results on Oct. 29, before the opening bell. Stay ...